Tag Archives:PI3K/MTOR inhibitor
Combining radiation with a PI3K/MTOR inhibitor
Patients with HPV-negative head and neck cancer (HNSCC) carry a poor prognosis despite optimal treatment with chemoradiation, with a 5 year survival of less than 50%. The future for this disease must lie in further escalation of
